Overview

A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

Status:
Terminated

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck. Ferumoxytol imaging will also be investigated at US sites as an exploratory endpoint.

Phase:

Phase 2

Details

Lead Sponsor:

BIND Therapeutics

Treatments:

Docetaxel